Ghent University Academic Bibliography

Rethinking CFTR variant responsiveness : differential responses to vanzacaftor and elexacaftor

Noelia Rodriguez Mier, Isabelle Callebaut, Marijke Proesmans, Eva Van Braeckel (UGent) , Stephanie Van Biervliet (UGent) , Mieke Boon, Anabela Santo Ramalho and François Vermeulen

(2026) JOURNAL OF CYSTIC FIBROSIS. 25(2). p.314-318

Add to list

Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population

Julie Semenchuk, Yumi Naito, Susan C Charman, Siobhán B Carr, Jamie Duckers, Stephanie Y Cheng, Bruce C Marshall, Albert Faro, Alexander Elbert, Christopher H Goss, et al.

(2026) JOURNAL OF CYSTIC FIBROSIS. 25(4). p.670-677

Add to list

Journal Article
A1
open access

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function : insights from a European multicenter survey

Andrea Gramegna, Carlo Magnoni, Chiara Premuda, Gianfranco Alicandro, Onno Akkerman, Adelina Amorim, Pilar Azevedo, Stephen Bourke, Vincenzo Carnovale, Filia Diamantea, et al.

(2026) JOURNAL OF CYSTIC FIBROSIS. 25(4). p.628-636

Add to list

Journal Article
A1
open access

Effects of elexacaftor/tezacaftor/ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis

Eva Van Braeckel (UGent) , Andrew T. Braun, Nicholas J. Simmonds, Peter J. Barry, Jane C. Davies, Marie E. Egan, Allen Lapey, Marcus A. Mall, Edward F. McKone, Daniel Peckham, et al.

(2026) JOURNAL OF CYSTIC FIBROSIS. 25(4). p.682-688

Add to list

Shifts in systemic inflammatory profiles on elexacaftor/tezacaftor/ivacaftor predict clinical outcomes in cystic fibrosis

Leander Jonckheere (UGent) , Lieve Vande Sande, Iris Janssens (UGent) , Yannick Vande Weygaerde (UGent) , Stephanie Van Biervliet (UGent) , Heidi Schaballie (UGent) , Petra Schelstraete (UGent) , Tania Maes (UGent) , Cedric Bosteels (UGent) and Eva Van Braeckel (UGent)

(2025) JOURNAL OF CYSTIC FIBROSIS. In Journal of Cystic Fibrosis 24(Supplement 1). p.S20-S20

Add to list

Cystic fibrosis as a modulable model for CFTR-related immune dysregulation

Leander Jonckheere (UGent) , Cedric Bosteels (UGent) , Iris Janssens (UGent) , Sebastian Riemann (UGent) , Lieve Vande Sande, Tania Maes (UGent) , Yannick Vande Weygaerde (UGent) , Stephanie Van Biervliet (UGent) , Filomeen Haerynck (UGent) , Bart Lambrecht (UGent) , et al.

(2025) JOURNAL OF CYSTIC FIBROSIS. In Journal of Cystic Fibrosis 24(Supplement 1). p.S108-S108

Add to list

European practices in vitamin supplementation for cystic fibrosis since the introduction of CFTR modulators

Dimitri Declercq (UGent) , M. O'Mahony, M.L.P. Kolsgaard, C. Schwarz and C. Smith

(2025) JOURNAL OF CYSTIC FIBROSIS. In Journal of Cystic Fibrosis 24(Supplement 1). p.S169-S169

Add to list

The use of tube feeding after starting elexacaftor/tezacaftor/ivacaftor in a Belgian paediatric and adult cohort living with CF

Dimitri Declercq (UGent) , Laurense Roose (UGent) , Yannick Vande Weygaerde (UGent) , Heidi Schaballie (UGent) and Stephanie Van Biervliet (UGent)

(2025) JOURNAL OF CYSTIC FIBROSIS. In Journal of Cystic Fibrosis 24(Supplement 1). p.S178-S178

Add to list

Active parents, active youth? Exploring the association between physical activity of youth with Cystic Fibrosis and their parents

Manon Kinaupenne (UGent) , Stephanie Van Biervliet (UGent) , Kim Van Hoorenbeeck, Heidi Schaballie (UGent) , Kristof Vandekerckhove (UGent) , Marieke De Craemer (UGent) and Heleen Demeyer (UGent)

(2025) JOURNAL OF CYSTIC FIBROSIS. 24(2). p.418-420

Add to list

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Henryk Mazurek, Andrzej Emeryk, Kamil Janeczek, Eric Derom (UGent) , Barbara Kuznar-Kaminska, Tomasz Leszek Grzywalski (UGent) , Adam Biniakowski, Krzysztof Szarzynski, Anna Pastusiak, Dominika Kaminiarczyk-Pyzalka, et al.

(2025) JOURNAL OF CYSTIC FIBROSIS. 24(2). p.390-397

Academic Bibliography

Rethinking CFTR variant responsiveness : differential responses to vanzacaftor and elexacaftor

Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function : insights from a European multicenter survey

Effects of elexacaftor/tezacaftor/ivacaftor on cough frequency, physical activity patterns, and sleep quality in adolescents and adults with cystic fibrosis

Shifts in systemic inflammatory profiles on elexacaftor/tezacaftor/ivacaftor predict clinical outcomes in cystic fibrosis

Cystic fibrosis as a modulable model for CFTR-related immune dysregulation

European practices in vitamin supplementation for cystic fibrosis since the introduction of CFTR modulators

The use of tube feeding after starting elexacaftor/tezacaftor/ivacaftor in a Belgian paediatric and adult cohort living with CF

Active parents, active youth? Exploring the association between physical activity of youth with Cystic Fibrosis and their parents

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Contents

Support

Contact